FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036761290> ?p ?o ?g. }

• W3036761290 endingPage "535" @default.
• W3036761290 startingPage "525" @default.
• W3036761290 abstract "Abstract Aims To estimate incidence and predictors of opioid agonist therapy (OAT) discontinuation in a national cohort of people who inject drugs (PWID). Design and Setting Annually repeated cross‐sectional serosurveillance among PWID attending ~50 needle–syringe programmes across Australia. Participants Between 1995 and 2018, 2651 PWID who reported current OAT and had subsequent survey participation completed 6739 surveys. Respondents were followed over 11 984 person‐years of observation (PYO). Respondents were predominantly male (60%), and the median age was 34 years. Heroin was the most commonly reported drug last injected (46%), and methadone was the most commonly prescribed OAT (77%). Measurements The primary outcome was discontinuation of OAT (methadone, buprenorphine or buprenorphine–naloxone). Among respondents who reported current OAT, those who did not report current OAT in all subsequent records were defined as discontinued, and those with current OAT at all subsequent records were defined as retained. Predictors of discontinuation included self‐reported demographic (sex, location, Indigenous status) and drug use characteristics (drug last injected, frequency of injection). Findings Just fewer than one‐third of respondents (29%) reported an OAT discontinuation event. The crude discontinuation rate was 6.3 [95% confidence intervals (CI) = 5.9–6.8] per 100 PYO. Discontinuation was significantly higher among respondents who reported last injecting pharmaceutical opioids [adjusted hazard ratio (aHR) = 1.75, 95% CI = 1.41–2.17, P < 0.001], being prescribed buprenorphine (aHR = 1.44, 95% CI = 1.18–1.76, P = 0.001) or buprenorphine–naloxone (aHR = 1.68, 95% CI = 1.20–2.34, P = 0.002), daily or more frequent injection (aHR = 1.51, 95% CI = 1.23–1.85, P < 0.001), recent public injecting (aHR = 1.37, 95% CI = 1.17–1.60, P < 0.001), incarceration in the previous 12 months (aHR = 1.31, 95% CI = 1.05–1.64, P = 0.017), recent receptive syringe or injection equipment sharing (aHR = 1.28, 95% CI = 1.10–1.48, P = 0.001) and male sex (aHR = 1.27, 95% CI = 1.09–1.47, P = 0.002). Conclusion People who inject drugs attending needle–syringe programmes in Australia appear to be significantly more likely to discontinue opioid agonist treatment if they were prescribed buprenorphine or buprenorphine–naloxone compared with methadone, are male or report injection risk behaviours and recent incarceration." @default.
• W3036761290 created "2020-06-25" @default.
• W3036761290 creator A5025372817 @default.
• W3036761290 creator A5046391653 @default.
• W3036761290 creator A5051748943 @default.
• W3036761290 creator A5087850879 @default.
• W3036761290 date "2020-07-14" @default.
• W3036761290 modified "2023-10-01" @default.
• W3036761290 title "Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia" @default.
• W3036761290 cites W1260361422 @default.
• W3036761290 cites W1500956687 @default.
• W3036761290 cites W1935962209 @default.
• W3036761290 cites W1966714873 @default.
• W3036761290 cites W1969345161 @default.
• W3036761290 cites W1974443246 @default.
• W3036761290 cites W1976965719 @default.
• W3036761290 cites W1989488351 @default.
• W3036761290 cites W1992194010 @default.
• W3036761290 cites W1993042950 @default.
• W3036761290 cites W2008795452 @default.
• W3036761290 cites W2020058133 @default.
• W3036761290 cites W2031591037 @default.
• W3036761290 cites W2032146607 @default.
• W3036761290 cites W2046232699 @default.
• W3036761290 cites W2051366813 @default.
• W3036761290 cites W2070467328 @default.
• W3036761290 cites W2075500103 @default.
• W3036761290 cites W2086728566 @default.
• W3036761290 cites W2102789712 @default.
• W3036761290 cites W2105534262 @default.
• W3036761290 cites W2105608370 @default.
• W3036761290 cites W2108791771 @default.
• W3036761290 cites W2110335781 @default.
• W3036761290 cites W2112956437 @default.
• W3036761290 cites W2124486489 @default.
• W3036761290 cites W2141627508 @default.
• W3036761290 cites W2151183844 @default.
• W3036761290 cites W2152004188 @default.
• W3036761290 cites W2155546477 @default.
• W3036761290 cites W2155993901 @default.
• W3036761290 cites W2207604103 @default.
• W3036761290 cites W2306163283 @default.
• W3036761290 cites W2315152690 @default.
• W3036761290 cites W2470822429 @default.
• W3036761290 cites W2496974376 @default.
• W3036761290 cites W2529759292 @default.
• W3036761290 cites W2579682140 @default.
• W3036761290 cites W2608446001 @default.
• W3036761290 cites W2753609137 @default.
• W3036761290 cites W2760696327 @default.
• W3036761290 cites W2790413422 @default.
• W3036761290 cites W2792080187 @default.
• W3036761290 cites W2888202338 @default.
• W3036761290 cites W2919155466 @default.
• W3036761290 cites W2938317137 @default.
• W3036761290 cites W2973674698 @default.
• W3036761290 cites W4232924730 @default.
• W3036761290 cites W4253918629 @default.
• W3036761290 cites W9286227 @default.
• W3036761290 doi "https://doi.org/10.1111/add.15168" @default.
• W3036761290 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32557931" @default.
• W3036761290 hasPublicationYear "2020" @default.
• W3036761290 type Work @default.
• W3036761290 sameAs 3036761290 @default.
• W3036761290 citedByCount "6" @default.
• W3036761290 countsByYear W30367612902021 @default.
• W3036761290 countsByYear W30367612902022 @default.
• W3036761290 countsByYear W30367612902023 @default.
• W3036761290 crossrefType "journal-article" @default.
• W3036761290 hasAuthorship W3036761290A5025372817 @default.
• W3036761290 hasAuthorship W3036761290A5046391653 @default.
• W3036761290 hasAuthorship W3036761290A5051748943 @default.
• W3036761290 hasAuthorship W3036761290A5087850879 @default.
• W3036761290 hasConcept C118552586 @default.
• W3036761290 hasConcept C120665830 @default.
• W3036761290 hasConcept C121332964 @default.
• W3036761290 hasConcept C126322002 @default.
• W3036761290 hasConcept C144024400 @default.
• W3036761290 hasConcept C149923435 @default.
• W3036761290 hasConcept C170493617 @default.
• W3036761290 hasConcept C207103383 @default.
• W3036761290 hasConcept C2778715236 @default.
• W3036761290 hasConcept C2778750930 @default.
• W3036761290 hasConcept C2778767360 @default.
• W3036761290 hasConcept C2778903686 @default.
• W3036761290 hasConcept C2778949969 @default.
• W3036761290 hasConcept C2780035454 @default.
• W3036761290 hasConcept C2781063702 @default.
• W3036761290 hasConcept C42219234 @default.
• W3036761290 hasConcept C44249647 @default.
• W3036761290 hasConcept C61511704 @default.
• W3036761290 hasConcept C71924100 @default.
• W3036761290 hasConceptScore W3036761290C118552586 @default.
• W3036761290 hasConceptScore W3036761290C120665830 @default.
• W3036761290 hasConceptScore W3036761290C121332964 @default.
• W3036761290 hasConceptScore W3036761290C126322002 @default.
• W3036761290 hasConceptScore W3036761290C144024400 @default.
• W3036761290 hasConceptScore W3036761290C149923435 @default.

• next